12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Company News  |  Other News

Inspire ophthalmic news

Inspire will reduce headcount by 65 (27%) to 175 and will discontinue its pulmonary program, including cystic fibrosis candidate denufosol to focus on its eye care business. In January, the second-generation P2Y2 receptor agonist missed the primary endpoint...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >